ClinicalTrials.gg
TerminatedNCT05070845Updated Oct 16, 2026

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

A Phase 2 interventional study of PF-06835375 in Primary Immune Thrombocytopenia, sponsored by Pfizer. Terminated at 24 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns.
Updated Oct 16, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia — 6 open to participants now, 9 under way, 4 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Australia.

Enrollment
18th of 28
61 · median 76
Started
2022
the only one that year
Phase 2
7 of 29
1 open now
Registered
19th of 29
by date

Among the 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 19th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (>3 months and ≤12 months), or chronic (>12 months) ITP

Read the detailed description

This study is designed to elucidate the effects of PF-06835375 on platelet counts in participants with moderate to severe primary ITP. Based on the experience with other B-cells depleting agents, it is expected that the platelet counts will increase following a standard treatment. Each participant in cohort 1 received 1 subcutaneous injection of dose 1 every month for 3 months during the 12-week treatment period. Each participant in cohorts 2, 3, or 4 (will) receive(d) subcutaneous injection(s) of dose 2, 3, or 4 every month for 4 months during the 16-week treatment period. This should provide sufficient levels of exposure and depletion of CXCR5 positive cells to sustain the effects of PF-06835375 during the treatment period. Additional depletion of Tfh cells may provide sustained increase in platelet count following the last treatment.

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • ITP
  • platelets
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Primary ITP. Ongoing ITP ( counts \<50 x 109/L) [No severe bleeding within 1 month or during screening] AND Persistent ITP (3 to 12 months) or Chronic ITP >12 months

Exclusion criteria

Exclusion Criteria:

  • Bleeding event according to the WHO grading scale ≥2 occurring ≤4 weeks prior to screen OR a current bleeding event that, in the opinion of the investigator, requires treatment with standard of care therapy OR require blood or blood products during screening
  • Splenectomy within 3 months of randomization or planned during the study duration.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Open Label PF-06835375 dose 1 Treatment

    subcutaneous injection once monthly for 3 months

    Biological: PF-06835375

  • Experimental
    Open Label PF-06835375 dose 2 Treatment

    subcutaneous injection once monthly for 4 months

    Biological: PF-06835375

  • Experimental
    Open Label PF-06835375 dose 3 Treatment

    subcutaneous injection once monthly for 4 months

    Biological: PF-06835375

  • Experimental
    Open Label PF-06835375 dose 4 Treatment

    subcutaneous injections once monthly for 4 months

    Biological: PF-06835375

Interventions

  • BiologicalPF-06835375

    CXCR5 inhibitor

06

What researchers measure

Primary outcomes

  1. Proportion of participants with change from baseline of platelet counts

    To evaluate absolute value of platelet count of treated participants

    Time frame: baseline through 12 and 16 weeks

Secondary outcomes

  1. proportion of participants with modified overall response (mOR)

    To evaluate the modified overall response of platelet count of treated participants

    Time frame: baseline through 12 and 16 weeks

  2. proportion of participants with complete response (CR)

    To evaluate the complete response of platelet count of treated participants

    Time frame: baseline through 12 and 16 weeks

  3. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    Time frame: baseline through end of study (Week 20 for cohort 1 and Week 24 for cohorts 2 and 3)

  4. Proportion of participants with change from baseline of platelet counts

    Time frame: baseline to Week 20 and Week 24

  5. Proportion of participants with change from baseline of circulating B cells

    Time frame: baseline to Week 20 and Week 24

  6. Proportion of participants with change from baseline of circulating cTfh cells

    Time frame: baseline to Week 20 and Week 24

07

Study locations

24 sites
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • South West Radiology
    Liverpool, New South Wales 2170, Australia
  • Slade Pharmacy
    Mount Kuring-Gai, New South Wales 2080, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • ICON Cancer Centre - Kurralta Park
    Kurralta Park, South Australia 5037, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Unity Health Toronto, St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Pécsi Tudományegyetem Klinikai Központ
    Pécs, Baranya 7624, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, Somogy County 7400, Hungary
  • Semmelweis University
    Budapest, 1088, Hungary
  • Tolna Varmegyei Balassa Janos Korhaz
    Szekszárd, 7100, Hungary
  • AIDPORT Sp. z o.o.
    Skórzewo, Greater Poland Voivodeship 60-185, Poland
  • InterHem
    Bialystok, 15-732, Poland
  • Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
  • Uniwersytecki Szpital Kliniczny w Poznaniu
    Poznan, 60-569, Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
    Wroclaw, 50-367, Poland
  • Hammersmith Hospital
    London, W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2022 to primary completion in Sep 2026, 55 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2028 → Sep 2026 and completion Aug 2028 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 7, 2021
StartActual
Feb 2, 2022
Primary completionActual
Sep 23, 2026was Aug 2028
CompletionActual
Sep 23, 2026was Aug 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns.
changed Oct 16, 2026
Sites
7 sites removed
Show 7 removed
  • Fakultni nemocnice Kralovske Vinohrady · Prague, Czechia
  • Vseobecna fakultni nemocnice v Praze · Prague, Czechia
  • Petz Aladár Egyetemi Oktató Kórház · Győr, Hungary
  • Komárom-Esztergom Vármegyei Szent Borbála Kórház · Tatabánya, Hungary
  • Addenbrooke's Hospital · Cambridge, United Kingdom
  • Derriford Hospital · Plymouth, United Kingdom
  • The Royal Cornwall Hospital · Truro, United Kingdom
Oct 16, 2026
Primary completion
Aug 2, 2028→Sep 23, 2026 (actual)
Oct 16, 2026
Study completion
Aug 2, 2028→Sep 23, 2026 (actual)
Oct 16, 2026
Enrollment
91 (estimated)→61 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Terminated
    Why stopped The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns.
    7 sites removed
    Show 7 removed
    • Fakultni nemocnice Kralovske Vinohrady · Prague, Czechia
    • Vseobecna fakultni nemocnice v Praze · Prague, Czechia
    • Petz Aladár Egyetemi Oktató Kórház · Győr, Hungary
    • Komárom-Esztergom Vármegyei Szent Borbála Kórház · Tatabánya, Hungary
    • Addenbrooke's Hospital · Cambridge, United Kingdom
    • Derriford Hospital · Plymouth, United Kingdom
    • The Royal Cornwall Hospital · Truro, United Kingdom
    Primary completion Aug 2, 2028→Sep 23, 2026 (now actual)
    Study completion Aug 2, 2028→Sep 23, 2026 (now actual)
    Enrollment 91 (estimated)→61 (actual)
    + 4 other changes: identifiers, verification date, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05070845
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 7, 2021
Start date
Feb 2, 2022
Primary completion
Sep 23, 2026
Completion
Sep 23, 2026
Last update
Oct 16, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion